61.11
-1.39 (-2.22%)
| Previous Close | 62.50 |
| Open | 62.50 |
| Volume | 13,123 |
| Avg. Volume (3M) | 40,570 |
| Market Cap | 1,972,740,864 |
| Price / Book | 12.53 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -1.18 |
| Total Debt/Equity (MRQ) | 0.37% |
| Current Ratio (MRQ) | 24.31 |
| Operating Cash Flow (TTM) | -29.23 M |
| Levered Free Cash Flow (TTM) | -13.42 M |
| Return on Assets (TTM) | -20.26% |
| Return on Equity (TTM) | -30.60% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Belite Bio, Inc | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.0 |
| Average | 1.38 |
|
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 54.27% |
| % Held by Institutions | 1.10% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 100.00 (HC Wainwright & Co., 63.64%) | Buy |
| Median | 90.00 (47.28%) | |
| Low | 80.00 (Benchmark, 30.91%) | Buy |
| Average | 90.00 (47.28%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 66.80 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Benchmark | 26 Mar 2025 | 80.00 (30.91%) | Buy | 65.21 |
| HC Wainwright & Co. | 18 Mar 2025 | 100.00 (63.64%) | Buy | 68.38 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |